Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Meanwhile, J&J is also exploring the use of amivantamab in patients who have failed TKI therapy and only have chemo as an option. Both lazertinib and amivantamab – which was developed using ...

WBRT and systemic treatments (chemotherapy and/or EGFR TKIs ... small Phase II trials suggest that BM patients benefit from TKI treatment, both in terms of radiological response and symptom ...

Image Source: Zacks Investment Research In August, the FDA approved Rybrevant in combination with oral EGFR-TKI inhibitor Lazcluze (lazertinib) as a chemotherapy-free treatment for a type of lung ...

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”) being jointly developed and commercialized by AstraZeneca and HUTCHMED. In 2023, savolitinib and ...

Imatinib is a first generation Tyrosine kinase inhibitor (TKI), it is not a chemotherapy agent, it is a targeted molecule ...